4.7 Article

The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism

Journal

CELL DEATH & DISEASE
Volume 13, Issue 11, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41419-022-05356-w

Keywords

-

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [RTG 2158, RTG 2578, STO 864/4-3, STO 864/5-1, STO 864/6-1]
  2. Dusseldorf School of Oncology (Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe)
  3. Dusseldorf School of Oncology (Medical Faculty of the Heinrich Heine University Dusseldorf)
  4. Projekt DEAL

Ask authors/readers for more resources

Viriditoxin (VDT), derived from Cladosporium cladosporioides, shows promising potential as a candidate for leukemia and lymphoma treatment. It exhibits high cytotoxicity in leukemia and lymphoma cells, while having minimal impact on solid tumor cells. Furthermore, VDT does not affect hematopoietic stem and progenitor cells, making it a potentially effective and safe therapeutic approach.
Inhibition of the mitochondrial metabolism offers a promising therapeutic approach for the treatment of cancer. Here, we identify the mycotoxin viriditoxin (VDT), derived from the endophytic fungus Cladosporium cladosporioides, as an interesting candidate for leukemia and lymphoma treatment. VDT displayed a high cytotoxic potential and rapid kinetics of caspase activation in Jurkat leukemia and Ramos lymphoma cells in contrast to solid tumor cells that were affected to a much lesser extent. Most remarkably, human hematopoietic stem and progenitor cells and peripheral blood mononuclear cells derived from healthy donors were profoundly resilient to VDT-induced cytotoxicity. Likewise, the colony-forming capacity was affected only at very high concentrations, which provides a therapeutic window for cancer treatment. Intriguingly, VDT could directly activate the mitochondrial apoptosis pathway in leukemia cells in the presence of antiapoptotic Bcl-2 proteins. The mitochondrial toxicity of VDT was further confirmed by inhibition of mitochondrial respiration, breakdown of the mitochondrial membrane potential (Delta psi m), the release of mitochondrial cytochrome c, generation of reactive oxygen species (ROS), processing of the dynamin-like GTPase OPA1 and subsequent fission of mitochondria. Thus, VDT-mediated targeting of mitochondrial oxidative phosphorylation (OXPHOS) might represent a promising therapeutic approach for the treatment of leukemia and lymphoma without affecting hematopoietic stem and progenitor cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available